Asset
OSI-027
Avalo Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04994002 | phase1 | withdrawn | 2021-09-03 | 2022-06-01 | Avalo Therapeutics, Inc. | A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations |
FDA applications (0)
This company has no applications containing this asset.